Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5NIH 4OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 34Gastrointestinal 19Thoracic 10Tumor-Agnostic 5Gynecologic 5Genitourinary 4Other solid neoplasm 3CNS 3Sarcoma 2Dermatologic 2Head & Neck 1

Conditions

Neoplasm Metastasis 4Neoplasms 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × trastuzumab deruxtecan × Tumor-Agnostic × Clear all
NCT04639219 2026-03-23

DPT01

AstraZeneca

Phase 2 Active not recruiting
102 enrolled 18 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT06174987 2025-10-15

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Daiichi Sankyo

Phase 3 Recruiting
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Daiichi Sankyo

Phase 2 Completed
79 enrolled 19 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT03383692 2023-12-11

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
40 enrolled 20 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡